{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:30:04Z","timestamp":1775208604734,"version":"3.50.1"},"reference-count":208,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells <jats:italic>via<\/jats:italic> the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing.<\/jats:p>","DOI":"10.3389\/fcvm.2020.568720","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T05:06:28Z","timestamp":1607058388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology"],"prefix":"10.3389","volume":"7","author":[{"given":"Sherry-Ann","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Zaharova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bicky","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ishizawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulrayz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaraman","family":"Kalyanaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Widlansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"B1","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fcvm.2019.00187","article-title":"Preventive cardio-oncology: the time has come","volume":"6","author":"Brown","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fcvm.2020.00145","article-title":"Innovation in precision cardio-oncology during the coronavirus pandemic and into a post-pandemic world","volume":"7","author":"Brown","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrclinonc.2015.168","article-title":"Systems biology approaches to adverse drug effects: the example of cardio-oncology","volume":"12","author":"Brown","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cpt.552","article-title":"Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches","volume":"101","author":"Brown","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s12265-020-09992-5","article-title":"Precision cardio-oncology: a systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"13","author":"Brown","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e015327","DOI":"10.1161\/JAHA.119.015327","article-title":"The role of angiotensin-converting enzyme inhibitors and \u03b2-blockers in primary prevention of cardiac dysfunction in breast cancer patients","volume":"9","author":"Brown","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ahj.2020.04.025","article-title":"A current review of COVID-19 for the cardiovascular specialist","volume":"226","author":"Lang","year":"2020","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaccao.2020.03.001","article-title":"The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer","volume":"2","author":"Ganatra","year":"2020","journal-title":"JACC CardioOncology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","article-title":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","volume":"65","author":"Barac","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11886-020-01293-2","article-title":"Cardiovascular risks in patients with COVID-19: potential mechanisms and areas of uncertainty","volume":"22","author":"Cheng","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2352-4642(20)30257-1","article-title":"SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome","volume":"4","author":"Dolhnikoff","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)","volume":"5","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e008719","DOI":"10.1161\/CIRCEP.120.008719","article-title":"Cardiac arrhythmias in COVID-19 infection","volume":"13","author":"Kochav","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s15010-020-01424-5","article-title":"First case of COVID-19 complicated with fulminant myocarditis: a case report and insights","volume":"48","author":"Zeng","year":"2020","journal-title":"Infection"},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11886-020-01292-3","article-title":"Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response","volume":"22","author":"Zhu","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jaccas.2020.04.009","article-title":"Cardiac tamponade secondary to COVID-19","volume":"2","author":"Dabbagh","year":"2020","journal-title":"JACC Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/S0140-6736(20)30912-0","article-title":"Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes","volume":"395","author":"Doyen","year":"2020","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/ejhf.1828","article-title":"Myocardial localization of coronavirus in COVID-19 cardiogenic shock","volume":"22","author":"Tavazzi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2362.2009.02153.x","article-title":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS","volume":"39","author":"Oudit","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacbts.2020.04.003","article-title":"COVID-19 clinical trials: a primer for the cardiovascular and cardio-oncology communities","volume":"5","author":"Ky","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jama.2020.4812","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","volume":"323","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11912-020-00945-4","article-title":"The COVID-19 pandemic and its impact on the cardio-oncology population","volume":"22","author":"Asokan","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11897-015-0258-4","article-title":"Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy","volume":"12","author":"Singh","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/heart.88.1.81","article-title":"Evaluation of long-term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques","volume":"88","author":"Meinardi","year":"2002","journal-title":"Heart"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review","volume":"73","author":"Sanz","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaccao.2020.01.007","article-title":"Early detection and prediction of anthracycline-induced right ventricular cardiotoxicity by 3-dimensional echocardiography","volume":"2","author":"Zhao","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e005384","DOI":"10.1161\/CIRCIMAGING.116.005384","article-title":"Prognostic value of right ventricular ejection fraction assessed by transthoracic 3D echocardiography","volume":"10","author":"Nagata","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.jcmg.2020.04.014","article-title":"Prognostic value of right ventricular longitudinal strain in patients with COVID-19","volume":"13","author":"Li","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.jcmg.2020.05.010","article-title":"Right ventricular dilation in hospitalized patients with COVID-19 infection","volume":"13","author":"Argulian","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s00134-015-4141-2","article-title":"Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact","volume":"42","author":"Mekontso Dessap","year":"2016","journal-title":"Intensive Care Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1164\/rccm.201002-0250OC","article-title":"Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury","volume":"182","author":"Bull","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s00134-009-1569-2","article-title":"Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome","volume":"35","author":"Mekontso Dessap","year":"2009","journal-title":"Intensive Care Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e200067","DOI":"10.1148\/ryct.2020200067","article-title":"COVID-19 complicated by acute pulmonary embolism","volume":"2","author":"Xie","year":"2020","journal-title":"Radiol Cardiothoracic Imaging"},{"key":"B45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.thromres.2020.04.011","article-title":"Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography","volume":"190","author":"Rotzinger","year":"2020","journal-title":"Thromb Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","article-title":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome","volume":"342","author":"Network","year":"2000","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1378\/chest.07-1013","article-title":"Prone positioning unloads the right ventricle in severe ARDS","volume":"132","author":"Vieillard-Baron","year":"2007","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone positioning in severe acute respiratory distress syndrome","volume":"368","author":"Gu\u00e9rin","year":"2013","journal-title":"N Engl J Med"},{"key":"B50","first-page":"e48","article-title":"Prone position in management of COVID-19 patients; a commentary","volume":"8","author":"Ghelichkhani","year":"2020","journal-title":"Arch Acad Emerg Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1530\/ERP-16-0020","article-title":"Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy","volume":"3","author":"Boczar","year":"2016","journal-title":"Echo Res Pract"},{"key":"B52","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (interagency registry for mechanically assisted circulatory support)","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","article-title":"Updates in anthracycline-mediated cardiotoxicity","volume":"9","author":"Nebigil","year":"2018","journal-title":"Front Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40169-017-0148-3","article-title":"Anthracycline induced cardiotoxicity: biomarkers and \u201cOmics\u201d technology in the era of patient specific care","volume":"6","author":"Moazeni","year":"2017","journal-title":"Clin Transl Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMsa2011686","article-title":"Hospitalization and mortality among black patients and white patients with covid-19","volume":"382","author":"Price-Haywood","year":"2020","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ajh.2011.182","article-title":"The ACE I\/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race\/ethnicity","volume":"25","author":"Ned","year":"2012","journal-title":"Am J Hypertens"},{"key":"B59","first-page":"A4815","article-title":"Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis\u2013a systematic review","volume":"61","author":"Fl\u00f8e","year":"2014","journal-title":"Dan Med J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"Mirsaeidi","year":"2015","journal-title":"Chest"},{"key":"B61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/gfx206","article-title":"Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis","volume":"33","author":"Trojanowicz","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cca.2020.03.031","article-title":"The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections","volume":"505","author":"Delanghe","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","article-title":"Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations","volume":"6","author":"Cao","year":"2020","journal-title":"Cell Discov"},{"key":"B64","first-page":"196","article-title":"Doxorubicin cardiotoxicity in African Americans","volume":"96","author":"Hasan","year":"2004","journal-title":"J Natl Med Assoc"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2017.05.019","article-title":"Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer","volume":"70","author":"Finkelman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.31260","article-title":"Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer","volume":"124","author":"Litvak","year":"2018","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cardfail.2014.05.012","article-title":"Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population","volume":"20","author":"Baron","year":"2014","journal-title":"J Card Fail"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2020.6548","article-title":"COVID-19 and African Americans","volume":"323","author":"Yancy","year":"2020","journal-title":"JAMA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1161\/CIRCULATIONAHA.120.048126","article-title":"At the heart of the matter: unmasking and addressing COVID-19's toll on diverse populations","volume":"142","author":"Haynes","year":"2020","journal-title":"Circulation"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0140-6736(20)30893-X","article-title":"COVID-19 exacerbating inequalities in the US","volume":"395","author":"Dorn","year":"2020","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"m1557","DOI":"10.1136\/bmj.m1557","article-title":"Mitigating the wider health effects of covid-19 pandemic response","volume":"369","author":"Douglas","year":"2020","journal-title":"BMJ"},{"key":"B73","doi-asserted-by":"publisher","first-page":"m1329","DOI":"10.1136\/bmj.m1329","article-title":"Socioeconomic gradient in health and the covid-19 outbreak","volume":"369","author":"Chung","year":"2020","journal-title":"BMJ"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1056\/NEJMc1901647","article-title":"Acute infection and myocardial infarction. Reply","volume":"380","author":"Musher","year":"2019","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M20-2566","article-title":"Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series","volume":"173","author":"Lax","year":"2020","journal-title":"Ann Intern Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.21.051912","article-title":"Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection","author":"Sharma","year":"2020","journal-title":"bioRxiv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.micinf.2013.08.003","article-title":"ACE2\u2014from the renin-angiotensin system to gut microbiota and malnutrition","volume":"15","author":"Perlot","year":"2013","journal-title":"Microbes Infect"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ndt\/gfv025","article-title":"Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease","volume":"30","author":"Anguiano","year":"2015","journal-title":"Nephrol Dial Transpl"},{"key":"B81","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00134-020-06028-z","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1016\/j.celrep.2019.11.113","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"29","author":"Garcia-Diaz","year":"2019","journal-title":"Cell Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40425-018-0401-3","article-title":"Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy","volume":"6","author":"Xie","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e20512","DOI":"10.1200\/JCO.2019.37.15_suppl.e20512","article-title":"Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1\/PD-L1 immune checkpoint blockers","volume":"37","author":"Medjebar","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B95","volume-title":"Features, Evaluation and Treatment Coronavirus (COVID-19)","author":"Cascella","year":"2020"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"B97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41423-020-00522-6","article-title":"Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019","volume":"17","author":"Huang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fphar.2020.01093","article-title":"Dynamic interleukin-6 level changes as a prognostic indicator in patients with COVID-19","volume":"11","author":"Liu","year":"2020","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jmv.25726","article-title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41375-020-0887-9","article-title":"SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine \u201cstorm\u201d and risk factor for damage of hematopoietic stem cells","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"key":"B104","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00134-020-06059-6","article-title":"Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation","volume":"46","author":"Leisman","year":"2020","journal-title":"Intensive Care Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1159\/000486061","article-title":"NLRP3 gene deletion attenuates angiotensin II-induced phenotypic transformation of vascular smooth muscle cells and vascular remodeling","volume":"44","author":"Ren","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B107","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fmicb.2019.00050","article-title":"Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","article-title":"Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease","volume":"44","author":"Schieffer","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000248135.97380.76","article-title":"Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism","volume":"48","author":"Luther","year":"2006","journal-title":"Hypertension"},{"key":"B110","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3324\/haematol.2009.006965","article-title":"A role for the renin-angiotensin system in hematopoiesis","volume":"94","author":"Park","year":"2009","journal-title":"Haematologica"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12015-020-10010-z","article-title":"SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45","volume":"20","author":"Ratajczak","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B117","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"Cook","year":"2011","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"","journal-title":"Lancet"},{"key":"B122","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMp030086","article-title":"Cancer-associated thrombosis","volume":"349","author":"Bick","year":"2003","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cca.2020.04.027","article-title":"Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis","volume":"507","author":"Henry","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1097\/01.CCM.0000171207.95319.B2","article-title":"Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors","volume":"33","author":"Cook","year":"2005","journal-title":"Crit Care Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e15833","DOI":"10.1097\/MD.0000000000015833","article-title":"The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-020-02134-3","article-title":"COVID-19 update: covid-19-associated coagulopathy","volume":"50","author":"Becker","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B130","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jth.13911","article-title":"Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis","volume":"16","author":"Iba","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B131","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/jth.12838","article-title":"Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH","volume":"13","author":"Thachil","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"B135","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.2147\/OTT.S223697","article-title":"Coexistence of a huge venous thromboembolism and bleeding tendency in cytokine release syndrome during CAR-T therapy","volume":"12","author":"Liu","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/j.bbmt.2019.12.430","article-title":"Incidence and management of venous thrombo-embolism (VTE) associated with CD19-directed chimeric antigen receptor (CAR) T-cell therapy: a single institution experience","volume":"26","author":"Hashmi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B137","doi-asserted-by":"publisher","first-page":"E202","DOI":"10.1002\/ccd.26379","article-title":"SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMc2009020","article-title":"ST-segment elevation in patients with Covid-19\u2014a case series","volume":"382","author":"Bangalore","year":"2020","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"NEJMoa2021436","DOI":"10.1101\/2020.06.22.20137273","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv"},{"key":"B141","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management. Systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"B144","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after t cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B149","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"B150","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study","volume":"24","author":"Kewan","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B153","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B155","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"B156","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.chom.2011.03.012","article-title":"The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry","volume":"9","author":"Morizono","year":"2011","journal-title":"Cell Host Microbe"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/mi.2014.129","article-title":"The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung","volume":"8","author":"Fujimori","year":"2015","journal-title":"Mucosal Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/2048872617740833","article-title":"Serum levels of growth arrest-specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction","volume":"8","author":"Caldentey","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B159","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines2020"},{"key":"B160","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/ijms21020604","article-title":"The role of CYP450 drug metabolism in precision cardio-oncology","volume":"21","author":"Fatunde","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","article-title":"The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer","volume":"51","author":"Iacovelli","year":"2015","journal-title":"Eur J Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/cancers12071750","article-title":"Renal and cardiovascular toxicities by new systemic treatments for prostate cancer","volume":"12","author":"Saltalamacchia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B164","first-page":"169","article-title":"Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?","volume":"16","author":"Angiolillo","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/cts.12815","article-title":"What do we know about remdesivir drug interactions?","volume":"13","author":"Yang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19\u2014preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"B169","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"Paranjpe","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30750-8","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JOP.19.00368","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary","volume":"15","author":"Key","year":"2019","journal-title":"J Oncol Pract"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"B173","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317242","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"B180","doi-asserted-by":"publisher","first-page":"214","DOI":"10.21037\/cdt.2019.04.05","article-title":"Reclassification of coronary heart disease risk in a primary prevention setting: traditional risk factor assessment","volume":"9","author":"Alashi","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.17.20104943","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19","author":"Khera","year":"2020","journal-title":"medRxiv"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.024752","article-title":"Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility","author":"Stawiski","year":"2020","journal-title":"bioRxiv"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.23.057042","article-title":"ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study","author":"Calcagnile","year":"2020","journal-title":"bioRxiv"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"B185","doi-asserted-by":"publisher","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B186","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cardfail.2020.04.013","article-title":"HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19","volume":"26","author":"Cardiology","year":"2020","journal-title":"J Card Fail"},{"key":"B187","volume-title":"Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers","author":"Simone","year":"2020"},{"key":"B188","unstructured":"COVID-19 and Its Implications for Thrombosis and Anticoagulation: ClinicalTrials.gov Identifier: NCT043170922020"},{"key":"B189","unstructured":"Lambrecht UH, Ghent\n            BartN\n          ClinicalTrials.gov2020"},{"key":"B190","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fcvm.2020.00078","article-title":"Cardiovascular impairment in COVID-19: learning from current options for cardiovascular anti-inflammatory therapy","volume":"7","author":"Wang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","volume":"5","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/eurheartj\/ehaa231","article-title":"Coronaviruses and the cardiovascular system: acute and long-term implications","volume":"41","author":"Xiong","year":"2020","journal-title":"Eur Heart J"},{"key":"B193","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fmicb.2019.00286","article-title":"Host lipids in positive-strand RNA virus genome replication","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Microbiol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.chom.2010.10.006","article-title":"Dengue virus-induced autophagy regulates lipid metabolism","volume":"8","author":"Heaton","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B196","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaccao.2020.04.003","article-title":"Cardio-oncology care in the time of COVID-19 and the role of telehealth","volume":"2","author":"Parikh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaccao.2020.04.001","article-title":"Modified routine cardiac imaging surveillance of adult cancer patients and survivors during the COVID-19 pandemic","volume":"2","author":"Calvillo-Arguelles","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.annepidem.2010.05.003","article-title":"Socio-economic and ethnic disparities in cardiovascular risk in the United States, 2001\u20132006","volume":"20","author":"Karlamangla","year":"2010","journal-title":"Ann Epidemiol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1161\/CIRCULATIONAHA.111.047480","article-title":"Twenty-two year trends in incidence of myocardial infarction, CHD mortality, and case-fatality in four US communities, 1987 to 2008","volume":"125","author":"Rosamond","year":"2012","journal-title":"Circulation"},{"key":"B200","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MAJ.0000000000000308","article-title":"Racial differences in hypertension: implications for high blood pressure management","volume":"348","author":"Lackland","year":"2014","journal-title":"Am J Med Sci"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/ijc.24054","article-title":"Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients","volume":"124","author":"Braithwaite","year":"2009","journal-title":"Int J Cancer"},{"key":"B202","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jchf.2018.02.015","article-title":"African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure","volume":"6","author":"Breathett","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B203","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.amjcard.2019.09.020","article-title":"Comparison of hydralazine\/nitrate and angiotensin receptor neprilysin inhibitor use among black versus nonblack americans with heart failure and reduced ejection fraction (from CHAMP-HF)","volume":"124","author":"Giblin","year":"2019","journal-title":"Am J Cardiol"},{"key":"B205","first-page":"35","article-title":"Effect of race and socioeconomic status on cardiovascular risk factor burden: the cooper center longitudinal study","volume":"23","author":"Frierson","year":"2013","journal-title":"Ethn Dis"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2015.66.3567","article-title":"Racial\/ethnic differences in adverse outcomes among childhood cancer survivors: the childhood cancer survivor study","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/jayao.2016.0016","article-title":"Effect of population socioeconomic and health system factors on medical care of childhood cancer survivors: a report from the childhood cancer survivor study","volume":"6","author":"Caplin","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMsb2021088","article-title":"Covid-19\u2014implications for the health care system","volume":"383","author":"Blumenthal","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.568720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T05:06:37Z","timestamp":1607058397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2020.568720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":208,"alternative-id":["10.3389\/fcvm.2020.568720"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2020.568720","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"article-number":"568720"}}